Evgeniya V. Tavlueva

Evgeniya V. Tavlueva

Auto-generated profile, based on publicly available information

Evgeniya V. Tavlueva

F.I. Inozemtsev City Clinical Hospital; National Medical Research Center for Therapy and Preventive Medicine

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2023 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ETE. V. Tavlueva
E. V. Tavlueva
OSO. N. Savkova
O. N. Savkova
EZE. V. Zernova
E. V. Zernova
SBS. A. Berns
S. A. Berns
ODOxana M. Drapkina
Oxana M. Drapkina
Aim. To evaluate the prevalence of oral anticoagulant therapy at the outpatient and inpatient stages in patients hospitalized with ischemic stroke.Material and methods. This open observational prospective real-world study included 114 patients with atrial fibrillation (AF) hospitalized with confirmed stroke.Results. Only 26,3% of patients with AF hospitalized with a confirmed diagnosis of ischemic stroke took anticoagulants (70% — direct oral anticoagulants (DOACs), 30% — warfarin). At the same time, among those taking warfarin, only one patient had normal international normalized ratio (INR) at the time of hospitalization (INR 2,6). In all other cases, the INR was <2. Of the 105 patients discharged at the outpatient stage, 93 (88,6%) patients were prescribed anticoagulants, and in most cases — DOACs (89 (84,8%)). 4 (3,8%) patients insisted on continuing warfarin therapy. There were following reasons for not prescribing DOACs: 4 (33,3%) patients were diagnosed with acute peptic ulcer during hospitalization, 2 (16,7%) — hemorrhagic transformation of the ischemic focus.Conclusion. One of the common reasons for stroke in outpatients with AF is the refusal to take oral anticoagulants or insufficient INR control when taking warfarin.

5 September 2023 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
SLS. V. Lukyanov
S. V. Lukyanov
YGYu. F. Glukhov
Yu. F. Glukhov
ETE. V. T.
E. V. T.
BTB. M. Tankhilevich
B. M. Tankhilevich
Dmitry ZateyshchikovDmitry Zateyshchikov
Dmitry Zateyshchikov
ЮГЮ. Ф. Глухов
Ю. Ф. Глухов
Aim. To study the safety and efficacy of Angipure in acute ST-segment elevation coronary syndrome (STE-ACS) and high-risk percutaneous transluminal coronary angioplasty (PTCA) compared with eptifibatide.Material and methods. The study included 157 patients with STE-ACS. High-risk PTCA included massive or total coronary artery thrombosis, noreflow/slow-reflow phenomenon, and acute stent thrombosis. Fifty-five people received Angipure at a dose of 0,72 mg/kg, 52 — at a dose of 0,40 mg/kg, while 50 patients received eptifibatide (Integrilin). We conducted clinical and laboratory studies, electrocardiography (ECG), coronary angiography.Results. According to the criteria "Frequency and severity of hemorrhagic events, including hemorrhagic stroke", "Frequency, severity of other adverse events", there were no differences in safety between Angipure at doses of 0,40 and 0,72 mg/kg and eptifibatide. Complaints, clinical symptoms, vital signs, complete blood count, biochemical and coagulation tests, ECG in patients of different groups were similar and had unidirectional dynamics. The use of Angipure or eptifibatide was considered effective if no adverse outcomes (death, recurrent acute ischemic event, need for urgent revascularization) were observed within 30 days. There were no lethal outcomes. One repeated acute ischemic event was registered in each group. In groups of patients receiving Angipure 0,40 mg/kg and eptifibatide, urgent revascularization was required once each.Conclusion. Angipure and eptifibatide have similar safety and efficacy.

7 September 2023 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
OAO. A. Abdullaev
O. A. Abdullaev
AAAlexander Arutyunov
Alexander Arutyunov
DVD. P. Vereshchak
D. P. Vereshchak
ETE. V. Tavlueva
E. V. Tavlueva
VKV. A. Konik
V. A. Konik
GAG. P. Arutyunov
G. P. Arutyunov
Aim. To evaluate the influence and changes of clinical and water-electrolyte parameters on the risk of cardiovascular events in the early period after decompensated heart failure (HF) in patients with type 2 diabetes (T2D), taking into account the influence of standard diuretic therapy and diuretic therapy in combination with sodium-glucose cotransporter 2 (SGLT-2) inhibitors.Material and methods. The study included 119 patients with type 2 diabetes and class III-IV HF. The duration of diagnosed HF at the time of enrollment was 6,9±1,1 years.Patients who met the inclusion criteria at the time of hospital admission were randomized into a group of standard therapy for decompensated HF (control group) and a group of combined diuretic therapy — loop diuretics + SGLT-2 inhibitors (main group).Results. Against the background of combined diuretic therapy with SGLT-2 inhibitors, a significant increase in diuresis was achieved, starting from the 2nd day: on day 2 — in the main group 1,342,83±159,74 ml/day and 1,250,17±134,53 ml/day in the control group (p=0,001, 95% confidence interval (CI)), on day 3, in the main — 1,895,17±249,95 ml/day, and in the control — 1,723,78±252,49 ml/day (p=0,004, 95% CI), on day 4, in the main — 2,382,50±246,29 ml/day and in the control — 2,124,83±2,86,44 ml/day (p=0,000002, 95% CI), on day 5, in the main — 2,785,50±282,38 ml/day and in the control group 2,458,39±273,36 ml/day (p<0,001, 95% CI).A comparison of the two groups showed a significant increase in natriuresis in the main group on day 5 (+111,1±10,54 ml) compared to the control (+75,53±15,01 ml, p<0,001, 95% CI). Extracellular fluid volume, determined by bioelectrical impedance analysis on day 5, decreased significantly higher when taking SGLT-2 inhibitors: in the main group the decrease was by 5,48±2,19 kg, in the control group — by 2,92±0,73 kg (p=0,02, 95% CI), On day 5, we revealed a significant inverse relationship between natriuresis level and extracellular fluid volume (r=0,217, p=0,018). Dapagliflozin (D), like empagliflozin (E), significantly and equally increases the level of natriuresis (D +108,25±13,56 mmol/day, p<0,001, E +112,52±8,50, p=0,00009) and reduces the extracellular fluid volume (D -5,05±1,46 kg, p<0,001, E -5,69±2,47, p<0,001) on day 5.Conclusion. In patients with type 2 diabetes hospitalized for decompensated HF, therapy with SGLT-2 inhibitors + loop diuretics lead to a significantly greater diuresis, natriuresis and a greater decrease in extracellular fluid volume. A significant inverse relationship was found between the extracellular fluid volume and natriuresis level on day 5. Dapagliflozin effectiveness in edema, assessed by natriuresis level on day of treatment, is identical to the empagliflozin.

23 April 2024 in Russian Journal of Preventive Medicine
Verified
Journal Article
Closed access
SBS.A. Berns
S.A. Berns
APA.A. Panfilova
A.A. Panfilova
SSS.I. Salichova
S.I. Salichova
EZE.V. Zernova
E.V. Zernova
MCM.A. Chadorich
M.A. Chadorich
ETE.V. Tavlueva
E.V. Tavlueva
Despite the fact that COronaVIrus Disease 2019 (COVID-19) primarily affects the respiratory system, it is known that many so-called post-COVID patients, who have no symptoms of acute infectious process, have long-term physiological, psychological and cognitive disorders. The most common complications are neurological. The article considers pathogenetic variants of affect with the Severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) of the central and peripheral nervous system, as well as neurological clinical manifestations in both acute and long-term periods of COVID-19. The analysis of literature data for the period of the pandemic from 2020 to 2023 was conducted.

17 February 2025 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
NSN. A. Shamalov
N. A. Shamalov
DKD. R. Khasanova
D. R. Khasanova
SMS. V. Marchenko
S. V. Marchenko
MSM. A. Soldatov
M. A. Soldatov
TAT. P Alekseeva
T. P Alekseeva
NMN. A. Marskaya
N. A. Marskaya
Thrombolytic therapy (TLT) of ischemic stroke (IS) with alteplase within the first 4.5 hours from the onset of symptoms is the most effective and proven method of treatment.Objective: to evaluate the safety and efficacy of TLT with Revelisa (alteplase) in IS in real-world clinical practice.Material and methods. The results of TLT with Revelisa were analyzed in 1181 patients with IS: 616 (52.2%) women and 565 (47.8%) men (mean age 68.28±12.56 years), of which 140 (11.9%) with staged reperfusion. The mean time from disease onset to TLT was 2.58±0.83 hours. The Heidelberg classification was used to assess hemorrhages during neuroimaging. Symptomatic hemorrhagic transformation (HT) was defined according to ECASS III criteria. The study group was characterized by high comorbidity: arterial hypertension (96.9%), ischemic heart disease (56.7%), chronic heart failure (55.8%) and cardiac arrhythmias (33.3%) were most common; diabetes mellitus was present in 23% of patients. IS occurred repeatedly in 15.4% of cases.Results. An improvement of 4 points or more on the NIHSS scale one day after TLT was observed in 41% of patients. The dynamics of the decrease in neurological symptoms one day later and at the time of discharge were statistically significant (p<0.001). The hospital mortality rate for the entire group was 8%, for the TLT group without endovascular intervention 5.6%. Twenty-nine patients (2.46%) had symptomatic HT, 14 of whom underwent endovascular intervention. The proportion of patients with a favorable clinical outcome (0–2 points on the modified Rankin scale) at discharge and at day 90 was 50.1% and 65.5%, respectively.Conclusion. The results of the PRIMA study confirm the high level of efficacy and safety of Revelisa in patients with IS, including during staged reperfusion. The data obtained are consistent with the published registry studies on alteplase in IS.

30 April 2024 in Kardiologiia
Verified
Journal Article
Open access
PDF file
SBS. A. Berns
S. A. Berns
MLM. S. Leontyeva
M. S. Leontyeva
ETE. V. Tavlueva
E. V. Tavlueva
VBV. S. Bashnyak
V. S. Bashnyak
ODOxana M. Drapkina
Oxana M. Drapkina
The aim of this review was to present the mechanism of infection with severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) and its possible effect on the course of arterial hypertension. Another aim was to evaluate the relationship of the renin-angiotensin-aldosterone system with the pathogenetic stages of infection caused by SARS-CoV-2 virus.